Submit Deal

SHIONOGI

HQ - Osaka

Summary

Shionogi is a discovery-based pharmaceutical company focused on developing new treatments to improve the lives of patients worldwide.

Deals Overview

Total Deals5

Valued Deals4

Total Value£ 1.24 B

Avg. Deal Size£ 311 M

Market Context

Senior Management

Nathan McCutcheon
President and CEO, Shionogi Inc
Isao Teshirogi
President and CEO
Masahiro Fujita
CFO

Sort

26 May 2020|United States|Biotechnology

Target: TETRA THERAPEUTICS

Bidder: SHIONOGI

7 Service Providers

5 Target | 2 Bidder

23 Dealmakers

18 Target | 5 Bidder

£ 410 M

Value

27 Jul 2020|China|Biotechnology

Target: PING AN / SHIONOGI JOINT VENTURE

Bidder: PING AN INSURANCE GROUP

3 Service Providers

3 Bidder

14 Dealmakers

14 Bidder

£ 609 M

Value

26 May 2021|United States|Digital Services

Target: AKILI INTERACTIVE LABS

Bidder: QUAD INVESTMENT MANAGEMENT

17 Service Providers

2 Target | 15 Bidder

24 Dealmakers

9 Target | 15 Bidder

£ 112 M

Value

25 Jun 2023|United States|Medical Services

Target: QPEX BIOPHARMA

Bidder: SHIONOGI

4 Service Providers

2 Target | 2 Bidder

23 Dealmakers

2 Target | 21 Bidder

£ 110 M

Value

22 Dec 2025|United States|Pharmaceuticals

Target: TANABE PHARMA CORP (RADICAVA BUSINESS)

Bidder: SHIONOGI

6 Service Providers

3 Target | 2 Bidder | 1 Vendor

3 Dealmakers

2 Bidder | 1 Vendor

n/a

Value